A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

Inclusion Criteria: * Locally advanced or metastatic solid tumors that have exhausted standard of care therapy * Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1 * Age \>21 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ and marrow function * For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit. * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Receiving any other investigational agents or any other anti-cancer therapy * Active autoimmune disease or a history of severe autoimmune disease or syndrome * History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * Pregnancy, lactating or breastfeeding women * History of primary CNS malignancy, or leptomeningeal disease or CNS metastases * Significant uncontrolled intercurrent illness that will limit the patient's ability to participate in the study * Inability to comply with study and follow up procedures